Head-To-Head Contrast: Centessa Pharmaceuticals (NASDAQ:CNTA) & Ainos (NASDAQ:AIMD)

Centessa Pharmaceuticals (NASDAQ:CNTA) and Ainos (NASDAQ:AIMD) are both medical companies, but which is the better investment? We will compare the two businesses based on the strength of their risk, earnings, analyst recommendations, institutional ownership, profitability, valuation and dividends.

Valuation & Earnings

This table compares Centessa Pharmaceuticals and Ainos”s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Centessa Pharmaceuticals	$15.00 million	226.66	-$235.76 million	($1.83)	-13.82
Ainos	$20,000.00	474.51	-$14.86 million	($3.98)	-0.50

Ainos has lower revenue, but higher earnings than Centessa Pharmaceuticals. Centessa Pharmaceuticals is trading at a lower price-to-earnings ratio than Ainos, indicating that it is currently the more affordable of the two stocks.

Insider & Institutional Ownership

82.0% of Centessa Pharmaceuticals shares are held by institutional investors. 7.1% of Centessa Pharmaceuticals shares are held by insiders. Comparatively, 9.8% of Ainos shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Profitability

This table compares Centessa Pharmaceuticals and Ainos’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Centessa Pharmaceuticals	N/A	-49.39%	-34.64%
Ainos	N/A	-119.36%	-58.78%

Analyst Ratings

This is a summary of current ratings and target prices for Centessa Pharmaceuticals and Ainos, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Centessa Pharmaceuticals	1	0	10	2	3.00
Ainos	1	0	0	0	1.00

Centessa Pharmaceuticals presently has a consensus target price of $37.70, suggesting a potential upside of 49.05%. Given Centessa Pharmaceuticals’ stronger consensus rating and higher probable upside, equities research analysts plainly believe Centessa Pharmaceuticals is more favorable than Ainos.

Volatility and Risk

Centessa Pharmaceuticals has a beta of 1.55, suggesting that its stock price is 55% more volatile than the S&P 500. Comparatively, Ainos has a beta of 2.39, suggesting that its stock price is 139% more volatile than the S&P 500.

Summary

Centessa Pharmaceuticals beats Ainos on 9 of the 14 factors compared between the two stocks.

About Centessa Pharmaceuticals

Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines for patients. Its products pipeline includes SerpinPC, an activated protein C inhibitor for the treatment of hemophilia A and B; and ORX750, an orally administered OX2R agonist for the treatment of narcolepsy and other sleep disorders. The company also develops LB101, a PD-L1xCD47 LockBody, a bi-specific monoclonal antibody for solid tumors, which is designed to selectively drive potent CD47 and CD3 effector function activity while avoiding systemic toxicity; and OX2R Agonists compounds are currently in development for the treatment of narcolepsy. In addition, its products pipeline comprises ORX750, an orally administered selective orexin receptor-2 (OX2R) agonist for the treatment of narcolepsy and other sleep disorders; and earlier-stage preclinical assets and discovery-stage programs. Centessa Pharmaceuticals plc was incorporated in 2020 and is headquartered in Altrincham, the United Kingdom.

About Ainos

Ainos, Inc., a healthcare company, engages in developing medical technologies for point-of-care testing and safe and novel medical treatment for disease indications. The company offers COVID-19 antigen rapid test kit and Ainos’ cloud-based test management App, a cloud-based test management platform comprising an antigen rapid test kit, a personal application, and an enterprise app; COVID-19 nucleic acid test; volatile organic compounds point-of-care testing; Very Low-Dose Oral Interferon Alpha, a low-dose oral interferon alpha formulation based IFN-a’s broad treatment applications; and Synthetic RNA developing a SRNA technology platform in Taiwan. It also provides women’s health, pneumonia, Ainos Pen, AI Nose, and other products. Ainos, Inc. was formerly known as Amarillo Biosciences, Inc. and changed its name to Ainos, Inc. in May 2021. The company was incorporated in 1984 and is based in San Diego, California.